Phase 3 Endometrial Cancer Trial, Recruiting NCT05764044 Sponsor: Hospital do Coracao Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 3 Endometrial Cancer Trial, Recruiting

NCT05764044
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with cervical cancer at a certain stage (moderately advanced to advanced, known as FIGO 2018 stage IB3 to IVA).
  • You have already received standard treatment combining chemotherapy and radiation therapy (chemoradiotherapy).
  • You are generally well enough to carry out normal daily activities, as measured by a standard health score, and are expected to live at least 12 weeks.
  • Your immune system is functioning normally.
  • A blood test taken after your chemoradiotherapy found traces of certain types of HPV (a virus linked to cervical cancer) in your bloodstream.
  • Your blood counts, liver, and kidney are working well enough to meet specific health thresholds (confirm with trial site for exact values).
  • If you are able to become pregnant, you must be willing to use an approved form of contraception during the trial and for 3 months after it ends.
  • You are willing to take part and have signed a consent form agreeing to the study procedures.

Who may not be able to join:

  • You have had cervical cancer before, or have had any other type of cancer.
  • You are currently pregnant.
  • You were unable to complete the standard chemotherapy and radiation treatment that was required before joining the trial.
  • Your tumor contains HPV types other than the specific ones listed in the trial criteria (confirm with trial site).
  • You do not have tissue biopsy results confirming your diagnosis, or you have not had the required tests to determine the stage of your cancer.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 11 999112805

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Hospital do Coracao
Registry
ClinicalTrials.gov
Start date
27 March 2024
Est. completion
31 December 2026

Where this trial is recruiting

🇧🇷 Brazil

Primary endpoints

Progression free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov